Testosterone transdermal - Transdermal Delivery Solutions

Drug Profile

Testosterone transdermal - Transdermal Delivery Solutions

Alternative Names: Testagen HypoSpray; Testagen TDS; Testosterone spray -Transdermal Delivery Solutions

Latest Information Update: 21 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Transdermal Delivery Solutions Corp
  • Developer St. Bartholomews Hospital; Transdermal Delivery Solutions Corp
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Eye disorder therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Testosterone agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Hypogonadism

Most Recent Events

  • 19 Apr 2016 Waiting for QC - MHRA approves CTAs for transdermal testosterone to begin phase III trials in hypogonadism
  • 01 Apr 2016 Transdermal Delivery Solutions initiates the phase II TRANSFERENCE trial for Hypogonadism in United Kingdom (NCT02733133)
  • 26 Jan 2016 Phase II development for Hypogonadism is ongoing in United Kingdom (transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top